Kornimate/medical-research-clean huggingface dataset:
cognitive and emotional factors in visual exploration among patients with schizophrenia

Conditions: Schizophrenia

Summary: background: patients with schizophrenia are abnormally disturbed by information onsets, which may result in a disadvantage in filtering relevant information. it seems that they accord the same importance to all objects in a scene without taking into account the relevance of objects (cognitive salience) or their emotional charge (salience emotional). the paradigm of change blindness offers the interesting possibility of studying sensitivity to the sudden irruption of visual information with ecological stimuli in schizophrenia. an increased attentional capture by the irruption of visual information would suggest better performance in patients than in healthy controls. moreover, patients are disturbed to processing of emotional information, in this way we would like to measure the impact of emotional salience on the visual exploration. main aim: the main objective is to evaluate, if patients with schizophrenia quickly detect changes occurring on irrelevant objects in the understanding of the scene. secondary objectives: to evaluate in patients with schizophrenia the impact of emotional salience using the same paradigm. to separate an explicit response (motors responses) with an implicit response (eye tracking measures). methodology: 30 patients with schizophrenia and 30 healthy controls were asked to detect changes in 96 scenes with 0 or 1 change (neutral or emotional changes). we will measure the participants' speed and accuracy in explicitly reporting the changes via motor responses and their capacity to implicitly detect changes via eye movements.

this study will include one visit: * written consent will be obtained from all participants * inclusion and exclusion criteria will be checked * an ophthalmologic test, a pregnancy test, a alcohol test and a salivary test will be realized * various symptoms will be assessed with the panss (positive and negative syndrome scale for schizophrenia) and the updrs (unified parkinson disease rating scale for patients, the moca (montreal cognitive assessment), the had (hospital anxiety and depression scale) and the mini (mini international neuropsychiatric interview) for all participants. * the task will be divided in two parts: a visuo-spatial task allowing to record saccadic eye movements (approximately 10 min). the change blindness session lasted approximately 20 min.

Eligibility criteria:
inclusion criteria: * normal or corrected vision * affiliate to a social security system * for group of patients with schizophrenia : diagnosis of schizophrenia based on the standard dsm-iv criteria and patients will be clinically stable at the testing time exclusion criteria: * history of neurological illness * pregnant and nursing women * drugs use in the last 24 hours * acute ocular disorder * under tutorship, curatorship or deprived of liberty * for controls group : be free dsm-iv axis-i diagnoses according the mini test.

Keywords: schizophrenia change blindness eye tracking implicit response
estimation of the placental volume by 3d ultrasound at 12, 16 and 22 weeks : relation with growth factors and d-dimers

Conditions: Placenta Vascular Malformation

Summary: pregnancy complications called pvp are mainly responsible for perinatal mortality. in these cases, the placenta is smaller and often the centre of thrombotic lesions. the estimation of the placenta volume by 3d ultrasound coupled with growth factors and d-dimers measures could improve the understanding of these pathologies to optimize their detection.

pregnancy complications called placental vascular pathologies (pvp) are mainly responsible for perinatal mortality. in these cases, the placenta is smaller and often the centre of thrombotic lesions. the estimation of the placenta volume by 3d ultrasound coupled with growth factors and d-dimers measures could improve the understanding of these pathologies to optimize their detection. thus, the identification of predictive factors of the risk of occurrence or recurrence of pvp could allow us to propose a monitoring of patients at risk, to anticipate corticoids administration for the foetuses pulmonary maturation and perhaps later to adapt anti hypertensive and antithrombotic therapeutics.

Eligibility criteria:
inclusion criteria: * previous history of one or more pvc episodes : preeclampsia, hellps, retroplacental hematoma, vascular iugr\ 2, unexplained iufd or iufd after abruption placentae, eclampsia. * coming for a 12 weeks ultrasound exclusion criteria: * multiple pregnancy * past history of in utero fetal death due to congenital malformations, rhesus incompatibility or an infection * previous history of iugr which etiology was a chromosomal, genic or infectious anomaly

Keywords: preeclampsia eclampsia retroplacental hematoma vascular iugr iufd placental volume
omitting completion axillary treatment in sentinel node positive breast cancer patients undergoing a mastectomy

Conditions: Breast Neoplasms

Summary: study aim to decrease the number of breast cancer patients receiving overtreatment of the axilla, in order to positively influence the axillary morbidity rate and quality of life. primary objective to determine whether omitting completion axillary treatment is not inferior to the current axillary treatment regimen in sentinel node positive breast cancer patients undergoing a mastectomy, in terms of regional recurrence rate. hypothesis completion axillary treatment can be safely omitted in sentinel node positive breast cancer patients undergoing a mastectomy. this will lead to a decreased axillary morbidity rate and to an increased quality of life, with non-inferior regional control, distant-disease free- and overall survival rates.


Eligibility criteria:
inclusion criteria: * female * aged 18 years or older * pathologically confirmed invasive unilateral breast carcinoma * a clinical t1-2 tumour (including multifocal or multicentric breast cancer) * will be or is treated with mastectomy * clinically node negative: no signs of axillary lymph node metastases at physical examination and preoperative axillary ultrasound (or negative cyto-/histopathology) * sentinel lymph node procedure and its pathologic evaluation should be performed according to the dutch breast cancer guideline * pn1mi(sn) or pn1(sn): at least one and a maximum of three axillary sentinel lymph nodes containing micro- and/or macrometastases * written informed consent exclusion criteria: * clinically node positive pre-operative * sentinel lymph nodes only containing isolated tumour cells (\<0.2 mm) * solitary parasternal sentinel lymph node metastasis (pn1b) * bilateral breast cancer * irradical resection of primary tumour at time of randomization (applicable in case the mastectomy is performed before randomization) * evidence of metastatic disease * history of invasive breast cancer * previous treatment of the axilla with surgery or radiotherapy (except surgery for hidradenitis suppurativa or for other superficially located skin lesions, such as naevi) * pregnant or nursing * other prior malignancies within the past 5 years (except successfully treated basal cell and squamous cell skin cancer, carcinoma in situ of the cervix or carcinoma in situ of the ipsilateral or contralateral breast) or unsuccessfully treated malignancies \> 5 years before randomization * unable or unwilling to give informed consent

Keywords: sentinel lymph node metastasis completion axillary lymph node dissection axillary radiotherapy
target-controlled infusion model for cefepime

Conditions: Antimicrobial Treatment

Summary: for this study, a previously developed population pharmacokinetic (poppk) model for cefepime (jonckheere et al., submitted to jac) was programmed in rugloop vii, which is a software program to drive an infusion pump. by entering patient data (such as gender, serum creatinine, age and weight) in rugloop ii, a patient-specific dose will be calculated and given to the patient. this concept is known as target controlled infusion (tci). the aim of this study is to prospectively validate the poppk model using tci.


Eligibility criteria:
inclusion criteria: * male or female patients of 18 years of age or older, admitted to the hospital icu and requiring administration of cefepime as part of their treatment * patients within the weight range of 50 -120kg * patients with calculated creatinine clearance within the range 15 to \> 90 ml/min, allocated to one of three groups as described above. * written informed consent, or if not possible surrogate consent, or if not possible declaration for inclusion in an emergency, patient informed consent being signed as soon as possible. * patient with an arterial catheter in place for other reason than the current study purpose exclusion criteria: * patients displaying acute or chronic renal failure requiring renal replacement therapy * pregnancy * moribund patients * known sensitivity or allergy to cefepime * inclusion in another study involving antimicrobial treatment. * patient participating in a research for which a period of exclusion is currently required by other study protocol, ethical committee or health authority. * patient already previously included in the trial

Keywords: target controlled infusion pharmacokinetics cefepime critically ill patients
influence of central obesity on the esophageal epithelial barrier

Conditions: Gastroesophageal Reflux; GERD

Summary: this study is being done to help understand why some people with an increased amount of central obesity, without gastroesophageal reflux, develop changes to the lining of their esophagus that can potentially lead to esophageal adenocarcinoma (cancer).


Eligibility criteria:
inclusion criteria: participants who are undergoing clinically indicated upper endoscopy with bravo ambulatory ph capsule (off reflux medications for 7 days), in the esophageal clinic at mayo clinic. exclusion criteria: 1. pre-existing or suspected barrett's esophagus (\> 1cm of columnar mucosa in esophagus on endoscopy 2. oral anticoagulation precluding endoscopic biopsies 3. patients with known hypersensitivity to fluorescein sodium.

Keywords: gastroesophageal reflux disease gerd barrett's esophagus esophageal adenocarcinoma
prostatic hyperplasia treatment and cancer prevention

Conditions: Prostatic Hyperplasia

Summary: treatment of patients with prostatic hyperplasia with topical papaverine.

patients with obstructive voiding and high psa to be studied for the regression of symptoms and declining psa.

Eligibility criteria:
inclusion criteria: * patients with symptoms e.g. obstructive voiding, hyperplasia and high psa exclusion criteria: * patients on chemotherapy * abnormal lab values e.g. liver function, gfr and cad
ambulation with labor epidural in obese women

Conditions: Obesity; Labor Onset and Length Abnormalities

Summary: the purpose of this study is to determine if ambulation with a labor epidural in place is associated with decreased rate of cesarean delivery in obese patients.

obese women are known to have increased risk of cesarean delivery and prolonged labors. low concentration epidural analgesia can achieve pain relief and allow for ambulation. prior investigations have not shown a benefit in cesarean delivery between those who ambulate with an epidural and those who do not. these studies were conducted in women with normal weights. it is unknown if ambulation with a labor epidural is beneficial in decreasing cesarean delivery among obese women. obese women at term with a singleton pregnancy will be enrolled in this pilot study. patients will receive their epidural analgesia when they desire per standard protocol at our institution. following epidural placement, a modified bromage score and straight leg test will be performed. if the patient passes the straight leg test and has a modified bromage score \> 6, they will be allowed to ambulate. they will be encouraged to ambulate for 20 minutes per hour with another adult alongside them. obstetric care will be standard of care. on postpartum day one, the patient will be administered a labor agentry scale. chart review will then be conducted to review maternal and neonatal outcomes.

Eligibility criteria:
inclusion criteria: subjects capable of giving consent singleton pregnancy nulliparous (defined as no previous pregnancy beyond 20 weeks 0 days) gestational age greater than or equal to 37 weeks bmi \> = 35 at time of delivery admission adult companion available anticipated vaginal delivery exclusion criteria: physical disability precluding ambulation magnesium administration contraindications to neuraxial analgesia cerclage in current pregnancy active labor dpe category iii fetal heart tracing fetal demise in utero
moxibustion reduces symptoms and improves quality of life in patients with allergic rhinitis

Conditions: Allergic Rhinitis

Summary: the objective of this randomized controlled clinical trial is to compare the therapeutic effect of moxibustion on allergic rhinitis. the main questions it aims to answer are: based on randomized controlled trials, verify the effectiveness of moxibustion in treating allergic rhinitis based on a real-time monitoring system for human surface temperature, discuss the differences in therapeutic effects of different moxibustion doses on allergic rhinitis

allergic rhinitis has a high incidence and is difficult to cure, seriously affecting the quality of life of patients compare the effects of different moxibustion durations on the clinical efficacy and body surface temperature of patients with allergic rhinitis, and preliminarily explore the impact of different moxibustion doses on the efficacy of heavy moxibustion treatment for allergic rhinitis, providing evidence-based basis for clinical practice.

Eligibility criteria:
inclusion criteria * those who meet the diagnostic criteria of chinese and western medicine for ar; * age range from 18 to 75 years old, regardless of gender; * patients and their families are informed and agree to the study. exclusion criteria * those who are undergoing other traditional chinese medicine external treatment methods; * those who have taken traditional chinese medicine recently or during treatment; * individuals who are allergic to heavy moxibustion smoke and dust; * individuals with concomitant bronchial asthma or other respiratory system diseases; * patients with severe skin diseases or ulcers in the local area where moxibustion is applied; * pregnant and lactating patients; * patients with severe diseases of important organs such as the heart, liver, lungs, and kidneys; * those who are unable to receive treatment according to regulations due to inconvenience in work, study, transportation, or personal activities

Keywords: allergic rhinitis moxibustion body surface temperature
use of the pressure right device after laparoscopic surgery

Conditions: Nausea; Vomiting

Summary: the primary objective is to test the hypothesis that the use of the pressure right device in combination with ondansetron and dexamethasone would result in a lower incidence of postoperative vomiting (emesis) than the combination of antiemetic therapy alone.

the study design is a randomized, double-blinded and sham-controlled evaluation of the adjunctive acupressure on the p6 point with pressure right to reduce the incidence of ponv and the need for rescue antiemetics leading to an improve quality of recovery after laparoscopic and ent surgery. the two proposed study groups are: group 1 (sham-control) 50 patients, will receive the sham pressure right (without acupressure button)30-45 min before induction of anesthesia and will be kept in place for 24h after discharge, and group 2 (pressure right) 50 patients, will receive the pressure right device 30-45 min before induction of anesthesia and will be kept in place for 24h after discharge. in addition, all 100 study patients will receive a combination of antiemetics (ondansetron and dexamethasone) during the surgery.

Eligibility criteria:
inclusion criteria: * patients scheduled to undergo major laparoscopic and ent surgery procedures under genertal anesthesia. * asa class i-iii adults of either sex * willingness and ability to sign an informed consent document. exclusion criteria: * patients with known allergy, hypersensitivity or contraindications to 5-ht3 antagonist. * patients experienced vomiting or retching within 24 h before surgery. * patients with clinically-significant medical conditions. * pregnant and lactating women.

Keywords: postoperative nausea & vomiting.
e-cuidachemo: telerehabilitation during chemotherapy in breast cancer

Conditions: Breast Cancer

Summary: patients with breast cancer undergo a series of psiclofisicas alterations during cancer treatment, chemotherapy phase being one of the more aggressive ete effect. these changes reduce the quality of life and result in a loss of physical health-related condition. studies have shown that the practice of physical exercise and rehabilitation strategies enhance or attenuate the impact of chemotherapy on quality of life of patients. at present, technological development from telerehabilitación systems is a promising strategy that enables fast and efficient communication between health professionals and patients, especially at this stage of the disease where the patient may encounter difficulties in matching measures improving their lifestyle with aggressive medical treatment. to carry out this study a controlled study masked, parallel-group done were conducted usual care control group and an intervention based on a web system telerehabilitación to improve the physical condition associated with health and performed quality of life.

the cuidate group will identify impairments of participants at baseline assessment. the aims based on weekly improvements will be set to facilitate the final goal. after each training session there will be feedback between the participant and the cuidate group to change or improve any exercise or activity. this feedback will allow to us to select adequate exercises and levels of difficulty. as a result, a modifiable personal training will be assigned to each one focusing on cardio-respiratory, mobility, and endurance performance through online system rehabilitation (using written instructions, hd videos, and audio files).

Eligibility criteria:
inclusion criteria: * diagnosis of stage i, ii, or iiia breast cancer * medical clearance of participation * access to the internet * basic ability to use a computer or living with someone who has this ability * in chemotherapy treatment at present moment; * have interest in improving lifestyle: fitness level * have signed informed consent exclusion criteria: * chronic disease or orthopedic issues that would interfere with ability to participate in a physical activity program;

Keywords: breast cancer telerehabilitation strength fatigue quality of life
a study to estimate the time course of pf-00241939 concentration in the blood following dosing by oral inhalation from dry powder inhalers

Conditions: Pharmacokinetics

Summary: the purpose of this study is to investigate the time course of pf-00241939 concentrations in the blood following dosing by oral inhalation using dry powder inhalers.


Eligibility criteria:
inclusion criteria: * healthy male and/or female subjects between the ages of 21 and 55 years. * body mass index (bmi) of 17.5 to 30.5 kg/m2; and a total body weight \>50 kg (110 lbs). exclusion criteria: * evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing). * pregnant or nursing females. * a positive urine drug screen.
surpass retrospective study

Conditions: Breast Cancer; Breast MRI; Neoadjuvant Systemic Therapy; Sentinel Lymph Node

Summary: this study aimed to determine whether sentinel lymph node biopsy (slnb) could be a reliable option for evaluating nodal status in patients who had responded well to neoadjuvant systemic therapy (nast), even if they had initially presented with a high nodal burden. the study investigated the outcomes of slnb followed by axillary lymph node dissection (alnd) in this patient population, taking into account the response to nast and the breast cancer subtype.

to determine the feasibility of sentinel lymph node biopsy (slnb) in this study, the investigators evaluated the false-negative rate (fnr) of slnb. the fnr was calculated as the number of patients with negative slns who had a residual disease in the rest of the axillary lymph nodes (alns) divided by the total number of patients with residual disease in either the slns, the rest of the alns, or both: fn/true-positive + fn. the investigators compared the fnr of the slnb according to the radiologic response measured using breast mri in each subtype. the investigators further evaluated the fnr in subgroups stratified by clinical nodal stage. additionally, the investigators assessed additional metastatic alns in cases with 1-2 metastatic slns through the completion of aln dissection.

Eligibility criteria:
inclusion criteria: * cn1-3 breast cancer at initial presentation * received neoadjuvant systemic therapy (nast) * received sentinel lymph node biopsy (slnb) followed by additional axillary lymph node dissection (alnd) * breast mri performed at baseline and post-nast. exclusion criteria: * case with unavailable data for breast mri and operation
smartheart validation study

Conditions: Cardiovascular Diseases

Summary: to compare the accuracy of novel smartphone or wearable ecg devices to a gold standard ecg in patients with normal and abnormal ecgs.

assess the effect of the following on the accuracy of the recorded ecg compared to a gold standard ecg: * posture or position of the patient * movement * amount of hair on the ecg site * skin condition (tone/dryness) ability to detect a paced rhythm accurately a qualitative assessment of ecg devices, including the amount of artefact in the signal and ease of use of the device

Eligibility criteria:
inclusion criteria: * participant is willing and able to give informed consent for participation in the study. * must have an adequate understanding of written and spoken english * able (in the investigators opinion) and willing to comply with study requirements. * must be over 18 years of age * must be deemed clinically stable by their direct care team. exclusion criteria: * subjects who do not have an adequate understanding of written and spoken english * patients who are medically unstable, as defined by the patient's direct care team. * patients who are unable to give informed consent * patients who are deemed clinically unstable by their direct care team

Keywords: wearable ecg electrocardiogram